Table 1. Patient demographics and other baseline characteristics (n=48).

Characteristics	All patients, n=48	Arm A, n=24	Arm AP, n=24	P
Age, years				0.510
Mean [range]	70.8 [65-80]	71.0 [65-80]	70.5 [66-79]
Gender, n [%]				0.917
Male	31 [64.6]	16 [66.7]	15 [62.5]
Female	17 [35.4]	8 [33.3]	9 [37.5]
ECOG PS, n [%]				0.401
0	17 [35.4]	10 [41.7]	7 [29.2]
1	31 [64.6]	14 [58.3]	17 [70.8]
TNM stage, n [%]				0.374
IIIB	13 [27.1]	8 [33.3]	5 [20.8]
IV	35 [72.9]	16 [66.7]	19 [79.2]
Histology, n [%]				0.471
Adenocarcinoma	32 [66.7]	17 [70.8]	15 [62.5]
Squamous	16 [33.3]	7 [29.2]	9 [37.5]
Smoking status, n [%]				0.474
Yes	27 [56.3]	15 [62.5]	12 [50.0]
No	21 [43.8]	9 [37.5]	12 [50.0]
EGFR mutation, n [%]				0.000
EGFR (–)	38 [79.2]	18 [75.0]	20 [83.3]
EGFR (+)	10 [20.8]	6 [25.0]	4 [16.7]
Pretreated with nab-paclitaxel				0.932
Yes	13 [27.1]	6 [25.0]	7 [29.2]
No	35 [72.9]	18 [75.0]	17 [70.8]
Prior treatment				1.000
Radiotherapy	7 [14.6]	4 [16.7]	3 [12.5]
Targeted therapy	18 [37.5]	10 [41.7]	8 [33.3]
Chemotherapy	42 [87.5]	20 [83.3]	22 [91.7]
Median treatment cycle	4 [1-8]	4 [2-8]	4 [1-6]	1.000

ECOG, Eastern Cooperative Oncology Group; PS, performance status; TNM, tumor node metastasis; EGFR, epidermal growth factor receptor.